Zoetis Inc.
ZTS Healthcare Drug Manufacturers Specialty & Generic
Zoetis Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.5 billion, up 2.28% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 2.48%, free cash flow grew 17.4% and total debt rose 37.5%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years, revenue growth for ten; insiders bought in the last twelve months.
Follow ZTS
Zoetis Inc. (ZTS) Revenue growth
Zoetis Inc.'s revenue growth over the twelve months to 30 June 2026 was 1.58%, down 0.7 percentage points from fiscal 2025 (2.28%). Over the past ten years it has ranged from −0.42% (fiscal 2015) to 16.5% (fiscal 2021); the current reading is higher than 18% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of 10.0% and below the Healthcare sector median of 8.27%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 2.28% | (6.05) |
| FY2024 | 8.33% | 2.59 |
| FY2023 | 5.74% | 1.83 |
| FY2022 | 3.91% | (12.58) |
| FY2021 | 16.5% | 9.86 |
| FY2020 | 6.63% | (0.84) |
| FY2019 | 7.47% | (2.29) |
| FY2018 | 9.76% | 1.19 |
| FY2017 | 8.57% | 5.99 |
| FY2016 | 2.58% | 3.00 |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Jun 2026 | −0.24% | (3.15) |
| Mar 2026 | 2.91% | (0.46) |
| Dec 2025 | 3.37% | 2.87 |
| Sep 2025 | 0.50% | (4.29) |
| 42 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| NBIX Neurocrine Biosciences, Inc. compare | 34.4% |
| ELAN Elanco Animal Health Incorporated compare | 12.0% |
| VTRS Viatris Inc. compare | 4.40% |
| TEVA Teva Pharmaceutical Industries Ltd. compare | 4.13% |
| UTHR United Therapeutics Corporation compare | 2.49% |
| ZTS Zoetis Inc. | 1.58% |
| TAK Takeda Pharmaceutical Co. compare | 0.66% |
| RDY Dr. Reddy's Laboratories Ltd compare | −11.6% |
| HLN Haleon PLC Sponsored ADR compare | — |
| Drug Manufacturers Specialty & Generic industry median | 10.0% |
| Healthcare sector median | 8.27% |
| Market median | 7.41% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on ZTS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement